Developer of a disruptive neural repair technology that utilizes in vivo astrocyte-to-neuron conversion
Location: United States, Pennsylvania, State College
Total raised: $10M
Investors 1
| Date | Name | Website |
| - | Foothill V... | foothill.v... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.09.2021 | Series A | $10M | - |
Mentions in press and media 6
| Date | Title | Description |
| 22.03.2024 | NeuExcell Therapeutics Announces Successful Dosing of First Patient by NeuroD1 Gene Therapy | SUZHOU, China, March 22, 2024 /PRNewswire/ -- NeuExcell Therapeutics, a leading biotechnology company focused on in vivo neural regenerative therapies, announces the successful dosing of the first patient with the first-in-class NeuroD1 gen... |
| 01.09.2021 | NeuExcell Therapeutics Raises Over $10M in Series Pre-A Funding | NeuExcell Therapeutics, a State College, Pa.- and Shanghai, China-based gene therapy company focusing on neurodegenerative diseases, raised $10+m in Series Pre-A financing. The round was led by Co-Win Ventures, joined by other institutional... |
| 30.08.2021 | NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth | STATE COLLEGE, Pa., Aug. 30, 2021 /PRNewswire/ -- NeuExcell Therapeutics (www.neuexcell.com), a gene therapy company focusing on neurodegenerative diseases, has announced a $10+ million Series Pre-A financing round. The round was led by Co-... |
| 30.08.2021 | NeuExcell Therapeutics : Raises $10+ Million Series Pre-A Round To Continue Its Company Growth | STATE COLLEGE, Pa., Aug. 30, 2021 /PRNewswire/ -- NeuExcell Therapeutics (www.neuexcell.com), a gene therapy company focusing on neurodegenerative diseases, has announced a $10+ million Series Pre-A financing round. The round was led by Co-... |
| 30.08.2021 | NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth | |
| - | Neuexcell Therapeutics | “NeuExcell” |